AtriCure (NSDQ:ATRC) posted third-quarter results today that beat the consensus forecast on Wall Street and maintained its outlook for the full year.

The Mason, Ohio-based atrial fibrillation (AFib) technology developer reported profits of $97.1 million, or $2.11 per diluted share, on sales of $70.5 million for the three months ended Sept. 30.